Home  |  Contact

UniProtKB/Swiss-Prot Q04637: Variant p.Thr161Ala

Eukaryotic translation initiation factor 4 gamma 1
Gene: EIF4G1
Variant information

Variant position:  161
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Threonine (T) to Alanine (A) at position 161 (T161A, p.Thr161Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  161
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1599
The length of the canonical sequence.

Location on the sequence:   YAGAYYPAQGVQQFPTGVAP  T PVLMNQPPQIAPKRERKTIR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YAGAYYPAQGVQQFPTGVAPTPVLMNQPPQIAPKRERKTIR

Mouse                         YAGAYYPAQGVQQFPASVAPAPVLMNQPPQIAPKRERKTIR

Rabbit                        -----------------------------------------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1599 Eukaryotic translation initiation factor 4 gamma 1
Alternative sequence 1 – 196 Missing. In isoform E and isoform 7.
Alternative sequence 1 – 164 Missing. In isoform D.
Mutagenesis 180 – 180 I -> A. Loss of PABPC1 binding.


Literature citations

Generation of multiple isoforms of eukaryotic translation initiation factor 4GI by use of alternate translation initiation codons.
Byrd M.P.; Zamora M.; Lloyd R.E.;
Mol. Cell. Biol. 22:4499-4511(2002)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8); VARIANTS ALA-161 AND VAL-432; ALTERNATIVE INITIATION;

The full-ORF clone resource of the German cDNA consortium.
Bechtel S.; Rosenfelder H.; Duda A.; Schmidt C.P.; Ernst U.; Wellenreuther R.; Mehrle A.; Schuster C.; Bahr A.; Bloecker H.; Heubner D.; Hoerlein A.; Michel G.; Wedler H.; Koehrer K.; Ottenwaelder B.; Poustka A.; Wiemann S.; Schupp I.;
BMC Genomics 8:399-399(2007)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A); VARIANT ALA-161;

Rotavirus RNA binding protein NSP3, interacts with eIF-4GI and evicts the poly(A) binding protein from eIF4F.
Piron M.; Vende P.; Cohen J.; Poncet D.;
EMBO J. 17:5811-5821(1998)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 30-206; NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 180-234; VARIANT ALA-161; INTERACTION WITH ROTAVIRAL NSP3;

Human eukaryotic translation initiation factor 4G (eIF4G) possesses two separate and independent binding sites for eIF4A.
Imataka H.; Sonenberg N.;
Mol. Cell. Biol. 17:6940-6947(1997)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 37-1599 (ISOFORM 8); INTERACTION WITH EIF4A; VARIANTS ALA-161 AND VAL-432; MUTAGENESIS OF LEU-768; LEU-771; PHE-776; 842-LEU-LEU-843; 851-PHE-GLU-852; LEU-896; ILE-902; LEU-905; ARG-974; PHE-977; LEU-985 AND TRP-990;

Translation initiator EIF4G1 mutations in familial Parkinson disease.
Chartier-Harlin M.C.; Dachsel J.C.; Vilarino-Guell C.; Lincoln S.J.; Lepretre F.; Hulihan M.M.; Kachergus J.; Milnerwood A.J.; Tapia L.; Song M.S.; Le Rhun E.; Mutez E.; Larvor L.; Duflot A.; Vanbesien-Mailliot C.; Kreisler A.; Ross O.A.; Nishioka K.; Soto-Ortolaza A.I.; Cobb S.A.; Melrose H.L.; Behrouz B.; Keeling B.H.; Bacon J.A.; Hentati E.; Williams L.; Yanagiya A.; Sonenberg N.; Lockhart P.J.; Zubair A.C.; Uitti R.J.; Aasly J.O.; Krygowska-Wajs A.; Opala G.; Wszolek Z.K.; Frigerio R.; Maraganore D.M.; Gosal D.; Lynch T.; Hutchinson M.; Bentivoglio A.R.; Valente E.M.; Nichols W.C.; Pankratz N.; Foroud T.; Gibson R.A.; Hentati F.; Dickson D.W.; Destee A.; Farrer M.J.;
Am. J. Hum. Genet. 89:398-406(2011)
Cited for: VARIANTS PARK18 VAL-502 AND HIS-1205; VARIANTS SER-71; ALA-161; CYS-311; VAL-432; 466-GLY--ALA-468 DEL; CYS-686; VAL-806; SER-829; ARG-1164; TRP-1197; ALA-1229; PRO-1233 AND SER-1257;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.